
CAS 1300037-86-8
:Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Tapentadol O-b-D-Glucuronide
CAS:Controlled Product<p>Applications A metabolite of Tapentadol (T007200).<br>References Terlinden, R., et al.: Eur. J. Drug Metab. Pharmacokinet., 32, 163 (2007), Tzschentke, T., et al.: J. Pharmacol. Exp. Ther., 323, 256 (2007), Wade, W., et al.: Clin. Ther., 31, 2804 (2009),<br></p>Formula:C20H31NO7Color and Shape:NeatMolecular weight:397.46Tapentadol O-b-D-Glucuronide (1 mg/ml in Methanol)
CAS:Controlled ProductFormula:C20H31NO7Color and Shape:ColourlessMolecular weight:397.46Tapentadol-d5 O-β-D-Glucuronide
CAS:Controlled ProductFormula:C20D5H26NO7Color and Shape:NeatMolecular weight:402.493Tapentadol-²-D-glucuronide solution
CAS:Controlled Product<p>Tapentadol is a centrally acting analgesic agent that binds to the µ-opioid receptor. Tapentadol is metabolized in the liver by glucuronidation and sulfation. Tapentadol 2-D-glucuronide is an active metabolite of tapentadol and exhibits a higher affinity for µ-opioid receptors than tapentadol. The clinical relevance of this metabolite has not been studied, but concentrations of tapentadol 2-D-glucuronide in plasma may be useful for monitoring therapeutic effects and for assessing side effects such as respiratory depression. It is believed that tapentadol 2-D-glucuronide binds to opioid receptors in the brain, spinal cord, and peripheral nervous system, which accounts for its analgesic properties. The clinical development of tapentadol was designed to assess its safety and efficacy in pediatric patients (ages 6–17 years). Plasma concentrations were measured using liquid chromatography</p>Formula:C20H31NO7Purity:Min. 95%Molecular weight:397.46 g/mol


